MicroRNA-572 expression in multiple sclerosis patients with different patterns of clinical progression

Journal of Translational Medicine

Volumn 13, Issue 1, 2015, Pages

  Mancuso, Roberta ^a   Hernis, Ambra ^a   Agostini, Simone ^a   Rovaris, Marco ^a   Caputo, Domenico ^a   Clerici, Mario ^a,b  

^a IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Disability; microRNA; Multiple sclerosis; NCAM; Remyelination; Serum

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; MICRORNA 572; UNCLASSIFIED DRUG; CD56 ANTIGEN; MIRN-572 MICRORNA, HUMAN; NCAM1 PROTEIN, HUMAN;

ADULT; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION REGULATION; HUMAN; MALE; MULTIPLE SCLEROSIS; PHENOTYPE; POLYMERASE CHAIN REACTION; RELAPSE; REMYELINIZATION; RNA ANALYSIS; UPREGULATION; CASE CONTROL STUDY; DISEASE COURSE; GENETICS; METABOLISM; MIDDLE AGED; MYELIN SHEATH; RECURRENT DISEASE;

ADULT; ANTIGENS, CD56; BIOMARKERS; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MALE; MICRORNAS; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; MYELIN SHEATH; PHENOTYPE; RECURRENCE;

EID: 84929154522     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-015-0504-2     Document Type: Article

References (38)

1. Franklin RJ, Ffrench-Constant C. Remyelination in the CNS: from biology to therapy. Nat Rev Neurosci. 2008;9:839-55.
2. Ingle GT, Stevenson VL, Miller DH, Thompson AJ. Primary progressive multiple sclerosis: a 5-year clinical and MR study. Brain. 2003;126:2528-36.
3. Lovas G, Szilágyi N, Majtényi K, Palvoktis M, Komoly S. Axonal changes in chronic demyelinated cervical spinal cord plaques. Brain. 2000;123:308-17.
4. Prineas JW, Barnard RO, Revesz T, Kwon EE, Sharer L, Cho ES. Multiple sclerosis: remyelination of nascent lesions. Ann Neurol. 1993;33:137-51.
5. Smith KJ, Blakemore WF, Mcdonald WI. Central remyelination restores secure conduction. Nature. 1979;280:395-6.
6. Kornek B, Storch MK, Weissert R, Wallstroem E, Stefferl A, Olsson T, et al. Multiple sclerosis and chronic autoimmune encephalomyelitis - a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J Pathol. 2000;157:267-76.
7. Olsen JA, Akirav EM. Remyelination in multiple sclerosis: cellular mechanisms and novel therapeutic approaches. J Neurosci Res. In press.
8. Frohman EM, Racke MK, Raine CS. Multiple sclerosis-the plaque and its pathogenesis. N Engl J Med. 2006;354:942-55.
9. Bramow S, Frischer JM, Lassmann H, Koch-Henriksen N, Lucchinetti CF, Sorensen PS, et al. Demyelination versus remyelination in progressive multiple sclerosis. Brain. 2010;133:2983-98.
10. Comi G, Filippi M, Martinelli V, Campi A, Rodegher M, Alberoni N, et al. Brain MRI correlates of cognitive impairment in primary and secondary progressive multiple sclerosis. J Neurol Sci. 1995;132:222-7.
11. Rutishauser U, Jessell TM. Cell adhesion molecules in vertebrate neural development. Physiol Rev. 1988;68:819-57.
12. Rutishauser U, Landmesser L. Polysialic acid in the vertebrate nervous system: a promoter of plasticity in cell-cell interactions. Trends Neurosci. 1996;19:422-7.
13. Brümmendorf T, Rathjen FG. Cell adhesion molecules 1: immunoglobulin superfamily. Protein Profile. 1995;2:963-1108.
14. Jørgensen OS. Neural cell adhesion molecule (NCAM) as a quantitative marker in synaptic remodeling. Neurochem Res. 1995;20:533-47.
15. Charles P, Hernandez MP, Stankoff B, Aigrot MS, Collin C, Rougon G, et al. Negative regulation of central nervous system myelination by polysialylated-neural cell adhesion molecule. Proc Natl Acad Sci U S A. 2000;97:7585-90.
16. Bhat S, Silberberg DH. Expression of neural cell adhesion molecule in dysmyelinating mutants. Brain Res. 1990;535:39-42.
17. Ono J, Harada K, Hasegawa T, Sakurai K, Kodaka R, Tanabe Y, et al. Central nervous system abnormalities in chromosome deletion at 11q23. Clin Genet. 1994;45:325-59.
18. Han MH, Hwang SI, Roy DB, Lungren DH, Price JV, Ousman SS, et al. Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature. 2008;451:1076-81.
19. Gnanapavan S, Ho P, Heywood W, Jackson S, Grant D, Rantell K, et al. Progression in multiple sclerosis is associated with low endogenous NCAM. J Neurochem. 2013;125:766-73.
20. Massaro AR, De Pascalis D, Carnevale A, Carbone G. The neural cell adhesion molecule (NCAM) present in the cerebrospinal fluid of multiple sclerosis patients is unsialylated. Eur Rev Med Pharmacol Sci. 2009;13:397-9.
21. Siegel SR, Mackenzie J, Chaplin G, Jablonski NG, Griffiths L. Circulating microRNAs involved in multiple sclerosis. Mol Biol Rep. 2012;39:6219-25.
22. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69:292-302.
23. Andersen CL, Jensen JL, Orntoft TF. Normalizatiopn of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res. 2004;64:5245-50.
24. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105:10513-8.
25. Gandhi R, Healy B, Gholipour T, Egorova S, Musallam A, Hussain MS, et al. Circulating microRNAs as biomarkers for disease staging in multiple sclerosis. Ann Neurol. 2013;73:729-40.
26. Fenoglio C, Ridolfi E, Cantoni C, De Riz M, Bonsi R, Serpente M, et al. Decreased circulating miRNA levels in patients with primary progressive multiple sclerosis. Mult Scler. 2013;19:1938-42.
27. Gnanapavan S, Giovannoni G. Neural cell adhesion molecules in brain plasticity and disease. Mult Scler Relat Disord. 2013;2:13-20.
28. Maness PF, Schachner M. Neural recognition molecules of the immunoglobulin superfamily: signaling transducers of axon guidance and neuronal migration. Nat Neurosci. 2007;10:19-26.
29. Dityatev A, Dityateva G, Sytnyk V, Delling M, Toni N, Nikonenko I, et al. Polysialylated neural cell adhesion molecule promotes remodeling and formation of hippocampal synapses. J Neurosci. 2004;24:9372-82.
30. Takeda Y, Murakami Y, Asou H, Uyemura K. The roles of cell adhesion molecules on the formation of peripheral myelin. Keio J Med. 2001;50:240-8.
31. Waschbisch A, Atiya M, Linker RA, Potapov S, Schwab S, Derfuss T. Glatiramer acetate treatment normalizes deregulated microRNA expression in relapsing remitting multiple sclerosis. PLoS One. 2011;6:e24604.
32. Mooren FC, Viereck J, Kruger K, Thum T. Circulating microRNAs as potential biomarkers of aerobic exercise capacity. Am J Physiol Heart Circ Physiol. 2014;306:H557-63.
33. Hromadnikova I, Kotlabova K, Hympanova L, Doucha J, Krofta L. First trimester screening of circulating C19MC microRNAs can predict subsequent onset of gestational hypertension. PLoS One. 2014;9:e113735.
34. van Rooij E. The art of microRNA research. Circ Res. 2011;108:219-34.
35. Brennaman LH, Maness PF. NCAM in neuropsychiatric and neurodegenerative disorders. Adv Exp Med Biol. 2010;663:299-317.
36. Massaro AR. The role of NCAM in remyelination. Neurol Sci. 2002;22:429-35.
37. Strekalova H, Buhmann C, Kleene R, Eggers C, Saffell J, Hemperly J, et al. Elevated levels of neural recognition molecule L1 in the cerebrospinal fluid of patients with Alzheimer disease and other dementia syndromes. Neurobiol Aging. 2006;27:1-9.
38. Maragkakis M, Alexiou P, Papadopoulos GL, Reczko M, Dalamagas T, Giannopoulos G, et al. Accurate microRNA target prediction correlates with protein repression levels. BMC Bioinformatics. 2009;10:295.